BiondVax Pharmaceuticals Ltd (BVXV) Actualités

Form NT 20-F - Notification of inability to timely file Form 20-F

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development...

Form SC 13D - General statement of acquisition of beneficial ownership

Scinai leadership to attend BIO-Europe Spring 2024

Scinai leadership to attend BIO-Europe Spring 2024 PR Newswire JERUSALEM, March 12, 2024 Showcasing Company's...

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Scinai Welcomes Liat Halpert as Head of Business Development and Sales PR Newswire JERUSALEM, Feb. 13, 2024...

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross...

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule PR Newswire JERUSALEM, Nov. 20, 2023 JERUSALEM, Nov. 20...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a...

Form 424B2 - Prospectus [Rule 424(b)(2)]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]